<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04674228</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2020-13238</org_study_id>
    <secondary_id>NCI-2020-13238</secondary_id>
    <secondary_id>N01-CN-2012-00042</secondary_id>
    <secondary_id>MAY2016-07-01F</secondary_id>
    <secondary_id>MAY2016-07-01F</secondary_id>
    <secondary_id>N01CN00042</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT04674228</nct_id>
  </id_info>
  <brief_title>Review of Post-Study Clinical Endoscopy Reports in Follow Up to MAY2016-07-01</brief_title>
  <official_title>Review of Post-Study Clinical Endoscopy Reports in Follow Up to MAY2016-07-01 Weekly Erlotinib for Familial Adenomatous Polyposis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study reviews post study clinical endoscopy reports in follow up to patients who&#xD;
      participated in MAY2016-07-01 with weekly erlotinib for familial adenomatous polyposis.&#xD;
      Reviewing follow up medical records may help researchers examine the extent of rapid&#xD;
      progression of familiar adenomatous polyposis disease burden after discontinuation of weekly&#xD;
      erlotinib.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To review clinical endoscopy reports, pathology reports, and other medical records related&#xD;
      to standard-of-care endoscopic evaluations for all participants in the parent study,&#xD;
      MAY2016-07-01, to determine the extent of reports of rapid progression of recurrent polyps&#xD;
      after completion intervention and follow up under the parent protocol.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients who participated in MAY2016-07-01 undergo review of medical records.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of study participants exhibiting clinically significant progression of duodenal neoplasia after completion of study drug</measure>
    <time_frame>At completion of study</time_frame>
    <description>Will be assessed by endoscopy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who underwent surgical resection</measure>
    <time_frame>At completion of study</time_frame>
    <description>Will determine the number of participants who underwent surgical resection for management of advanced upper gastrointestinal (GI) neoplasia/cancer between the date of completion of intervention and 2/28/2021.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who required endoscopic resection of advanced upper gastrointestinal (GI) neoplasms</measure>
    <time_frame>At completion of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with evidence of progression of upper GI disease</measure>
    <time_frame>At completion of study</time_frame>
    <description>Will be calculated by increase in Spigelman stage.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Familial Adenomatous Polyposis</condition>
  <arm_group>
    <arm_group_label>Observational (medical record review)</arm_group_label>
    <description>Patients who participated in MAY2016-07-01 undergo review of medical records.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electronic Health Record Review</intervention_name>
    <description>Review of medical records</description>
    <arm_group_label>Observational (medical record review)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants in MAY2016-07-01 Phase II Trial of Weekly Erlotinib Dosing to Reduce Duodenal&#xD;
        Polyp Burden Associated with Familial Adenomatous Polyposis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  MAY2016-07-01 study participants for whom medical records are available and accessible&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  MAY2016-07-01 study participants who have opted out of medical records reviews or for&#xD;
             whom consent for medical record review cannot be confirmed/documented&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niloy J Samadder</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic in Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niloy J. Samadder</last_name>
      <email>Samadder.jewel@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Niloy J. Samadder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eduardo Vilar-Sanchez</last_name>
      <email>evilar@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Eduardo Vilar-Sanchez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenomatous Polyposis Coli</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.</ipd_description>
    <ipd_url>https://grants.nih.gov/policy/sharing.htm</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

